-
Share
3,387 Posts.
4561
11/01/21
23:35
Share
I'm in with an initial position at 76c.
- TAM is sizeable relative to current valuation
- Valuation drivers are both clinical and regulatory
- Strong protected patent position
- Strong balance sheet with circa $33M in cash
- EV of circa $30M, which is very low for a biopharmaceutical company moving into phase 3 trials
- Dr Tom Duthy has a very solid reputation, happy to see him on board as a Director
- Share price currently very low relative to its historical movements and seems to have bottomed out
T.E.P.
